GeoVax Labs, Inc.

NasdaqCM GOVX

GeoVax Labs, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -0.82

GeoVax Labs, Inc. Price to Earnings Ratio (P/E) is -0.82 on January 14, 2025, a -13.05% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

GeoVax Labs, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.15 on June 17, 2024, which is 81.73% above the current Price to Earnings Ratio (P/E).
GeoVax Labs, Inc. 52-week low Price to Earnings Ratio (P/E) is -1.26 on November 12, 2024, which is -54.03% below the current Price to Earnings Ratio (P/E).
GeoVax Labs, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.47.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: GOVX

GeoVax Labs, Inc.

CEO	Mr. David Alan Dodd
IPO Date	Sept. 25, 2020
Location	United States
Headquarters	1900 Lake Park Drive
Employees	17
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Key trends

Past 5 years